maintain buy rate cut target heel bio
entri definit agreement merg option like core
industri trend expect on-going movement toward home see tangibl
strateg benefit scale synergi broaden payor access product
offer deal expect improv bio capit structur carri
full valuat addit execut remain key pro forma leverag
expect still heavi maintain buy cut pt
pro forma ebitda
bio merg option friday bio announc entri
definit agreement merg option privat home infus
compani own invest fund affili madison dearborn partner
walgreen hold upon complet bio issu
share estim assum debt suggest full
valuat multipl bio sharehold outstand share
make remaind combin creat
largest independ home infus provid led
option ceo john rademach cfo mike shapiro option
gener revenu ebitda suggest pro forma
adjust ebitda per present inclus expect
run-rat cost synergi anticip realiz within year
deal expect close second half
deal carri strateg merit benefit home infus gain
increas recognit move toward valu base care acceler
see number benefit merger aid combin
compani abil drive long term growth option bring sizabl
nation footprint locat state full servic pharmaci
ambulatori infus suit pro forma compani cover
 popul addit deal expand access limit distribut
drug enhanc clinic firepow broaden payor relationship option
contract top mco medicar medicaid
contract provid state compani expect merger
gener run-rat cost synergi within two year look quit
doabl us tie larg suppli chain/procur oper effici
administr synergi complement bio exist vision
initi importantli combin would improv capit structur
liquid posit detail
tr target
infus remain place remain bullish underli driver
home infus industri given meaning cost advantag vs institut patient prefer
abil deliv high qualiti cost effect care see combin compani well posit
benefit payor increasingli focu site care re-direct virtu treatment
home on-going push toward valu base care world patient increasingli
spend money demand value/conveni think low cost/mor
conveni home infus model dovetail nice market backdrop also think potenti
combin posit largest independ home/altern site infus servic provid
offer competit advantag expect overarch market driver drive solid industri
growth see factor could enhanc trend bios/opt combin
final industri highli fragment payor mix commerci includ
one key expect benefit propos merger improv simplifi
capit structur near-term matur lower cost capit increas liquid
combin would notic improv leverag pro forma leverag base commit
financ time deal announc cash flow remain critic given still heavi debt
load would expect de-lever time tie ebitda growth debt paydown like low
cap ex busi model aid cash flow see attract potenti opportun longer-
term highli fragment market
soft result lower estim target execut paramount result came
light revenu consensu larg tie weaker
anticip decemb growth bad debt adjust adjust ebitda margin
weigh bad debt adjust came well estim vs strhe
drove adjust ebitda vs strhe liquid tighten
year end disappoint compani seen re-acceler quarter date
gross revenu first two month year cut
stand-alone bio adjust ebitda reflect conserv
assumpt around cure bad debt price target base pro forma
adjust ebitda tie follow assumpt manag expect share
debt option care/combin compani adjust ebitda growth fairli ratabl synergi
captur noth increment cure close
page
revenu
revenu
revenu
revenu
revenu
revenu
page
bioscrip nation provid infus servic compani locat includ
home infus locat nurs locat two contract infus pharmaci bio partner
patient physician hospit healthcar payor pharmaceut manufactur provid
clinic manag solut deliveri cost-effect access prescript medic larg
home pend merger option add scale enhanc therapi offer
provid attract synergi improv capit structur
continu recogn inher valu core busi compani servic carri
benefit patient prefer treat home payor lower-cost set oper
collect improv encourag on-going mix shift toward attract core
busi expand margin pend merger option provid strateg
benefit time continu progress oper financi improv remain key
given heavi debt load view risk/reward favor
valuat risk
price target base stock trade adjust ebitda discount
current pro forma multipl risk rate price target includ integr challeng
pend option merger neg cash flow deterior mix failur pay debt load
failur execut strateg initi
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
